13 April 2023
Patients
...
-
14 November 2023
-
14 November 2023
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
PARIS, FRANCE, 13 November, 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced full results from the pivotal Phase III ELATIVE® trial, which are being presented in a late-breaking oral session (Abstract #484,...
-
29 February 2024
- 4 mins read
-
29 February 2024
- 4 mins read
Shared decision-making: A true patient-centric approach to care
Monia Vial, Senior Vice President, Franchise Head, Rare Disease Business Unit at Ipsen reflects on a conversation with Courageous Parents Network to educate Ipsen colleagues about shared decision-making and potential positive impacts when we better underst...
-
05 June 2023
-
05 June 2023
State Supplement Website Privacy Notice
This State Supplemental Privacy Policy (“Supplement”) applies only to information collected about consumers of US states with comprehensive privacy legislation that requires provision of a privacy notice. It provides information required under the Cali...
-
12 May 2023
- 4 mins read
-
12 May 2023
- 4 mins read
Understanding the true impact of living with FOP
This year marks the 17th anniversary since the discovery of the ACVR1 gene was announced, a major scientific milestone in fibrodysplasia ossificans progressiva (FOP) research that helped us understand what causes the condition. On April 23, ...
-
16 August 2023
-
16 August 2023
US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
PARIS, FRANCE, 16 August 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated for the reduction in volume of new heterotopic ossific...
-
13 April 2023
-
13 April 2023
Who We Are
Ipsen’s products are registered in 88 countries. With 5,000 employees working to create value for patients and society around the world, we have global reach while remaining an agile, mid-sized company....